Eva said it was effect to early stage patients with ALS. I think the cells therapy is only working for the early stage patient with ALS. The total cells number should be more than 2 Mils. Also the ways of injections should be very sophisticated. The Phase 2 study has enrolled early stage patients with ALS and increases the cell number. The outcome should be promising.
We are about to get data from STEM.....
Congress of Neurological Surgeons Annual Meeting
Excerpt from WSJ article titled....."StemCells, Inc. Announces Investigators From Two Clinical Trials to Present at Congress of Neurological Surgeons Annual Meeting"
The first presentation, scheduled for 2:36 p.m. Pacific Time on Monday, October 21, will be given by Nathan Selden, MD, PhD, FACS, FAAP, who was co-principal investigator in the Company's Phase I clinical study in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten's disease) and the four-year long-term observational study that followed. Dr. Selden will present a summary of the results from the long-term follow up study, which includes data from patients who are now more than five years after transplantation of the Company's proprietary HuCNS-SC(R) cells. Dr. Selden is Campagna Chair of Pediatric Neurosurgery at Doernbecher Children's Hospital and Oregon Health & Science University.
The second presentation, scheduled for 2:28 p.m. Pacific Time on Wednesday, October 23, will be given by Raphael Guzman, MD, who is co-principal investigator for the Company's Phase I/II study for chronic spinal cord injury currently underway in Switzerland, Canada, and the United States. Dr. Guzman will review interim results from that study, which to date has enrolled and dosed seven of the 12 patients planned. Dr. Guzman is Chief of Pediatric Neurosurgery and Vice Chair, Department of Neurosurgery at the University of Basel.
Eva provides all these allusions that it works in a subset of patients, then chokes at ANA where she says, I don't know if it works. Total loss of credibility. Just look at the previous journalism of her statements versus ANA. Fraud.
One theme emerging from the earlier cohorts was that patients with bulbar signs "did not do well," Feldman said.
-- She is doing her job, managing expectations. This is a terrible disease and patients deserve to know the truth. Hope phase II results show more promise but she is right to remain cautious.
It is a terrible job to be inconsistent. How do you explain her earlier positive conclusions versus this one? This company needs professional management. Advertising attending a rubber chicken dinner? I'm glad they went to dinner in Atlanta - maybe they need to focus on meeting all the guidance they've blown. Beijing stroke trial, MDD NSI 189 results, ALS Mexico -- and a ridiculous SCI program that is far behind STEMs.